Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With Actue Coronary Syndrome

Actue Coronary Syndrome Clinical Trial

Official title:

Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With Actue Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03658577
• Other study ID #: COE20180821
• Status: Recruiting
• Start date: March 2, 2018
• Est. completion date: December 2023

Study information

• Verified date: August 2018
• Source: Shenzhen People's Hospital
• Contact: Feng Lin, MD
• Phone: +8613510730251
• Email: 119538892[@]qq.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Limited data are available on the efficacy of beta-blocker therapy for secondary prevention in Actue Coronary Syndrome(ACS) patients. This study sought to investigate the association of beta-blocker therapy at discharge with clinical outcomes in patients with ACS after percutaneous coronary intervention (PCI).

Description:

The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommend beta-blockers for secondary prevention in patients with ACS without regard to reperfusion therapy. However, evidence supporting this recommendation originated from studies conducted before the introduction of reperfusion therapy or studies in patients treated with fibrinolysis. In the present era of PCI, there are no prospective randomized studies looking at the effects of long-term beta-blocker therapy on clinical outcomes in ACS patients. Moreover, results from registry data and post-hoc analysis on beta-blocker therapy in patients undergoing PCI are inconsistent.

In particular, the beneficial effect of long-term beta-blocker therapy has not been well established in patients with relatively low risk, such as preserved left ventricular systolic function or single-vessel disease. Therefore, we investigated the association of beta-blocker therapy at discharge with clinical outcomes in ACS patients after PCI.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 582
• Est. completion date: December 2023
• Est. primary completion date: August 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. consecutive patients 18 years of age or older;

2. patients diagnosed as ACS(including STEMI?NSTEMI and UA) by doctor at discharge;

3. patients undergoing primary PCI.

Exclusion Criteria:

missing beta-blocker information.

Related Conditions & MeSH terms

• Actue Coronary Syndrome
• Syndrome

Locations

Country	Name	City	State
China	Shenzhen People's Hospital	Shenzhen	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Shenzhen People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	all-cause death	The primary outcome was all-cause death during follow up.	3 years
Secondary	MACE	Secondary outcomes included major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction, stroke, any revascularization during follow-up	3 year